Gone from iHub.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The CEO set up an investment company to dump shares as fast as possible. That's what Kalani does.
So the question everyone should ask is: Is the CEO dumping shares as fast as possible because:
1. he wants to be generous with shareholders
2. he wants to continue his more than decade-long rape of shareholders
This is very significant.
No real investor would buy stock in a company knowing that it gave him no control at all.
Dryships has lots of types of preferred stock, all designed to ensure that the common stock remains totally worthless.
I have to admit this 6K I like seeing 10 year tine charter contracts in place for new vessels! Previous acquisition had 5 years contracts associated to those vessels...
A few years ago Dryships claimed they had billions of dollars in signed contracts and backlogs.
Since then the stock has fallen from over 100,000 dollars per share to 1.24.
If you invest a hundred thousand dollars today don't be surprised if you can't afford a Starbucks coffee with your investment in a few years.
NO BODY knows if the commons will survive
People are overpaying for what they greedily hope is a lottery ticket. The problem for them is that the ticket has expired and is clearly worthless.
The fact that the stock has lost over 99%, but not exactly 100%, of its value doesn't constitute proof that it's not worthless.
No institutional investors would consider buying a company like this where the CEO runs it like his private piggy bank.
Becoming a shareholder gives you no rights at all. The CEO repeatedly grants himself special shares that allow him to control all the company's votes.
Dryships gets a failing grade.
http://www.investopedia.com/terms/c/corporategovernance.asp
Sunedison went bankrupt on April 21st, 2016.
At that time it was obvious that the stock was completely worthless.
Nobody in politics on April 21st 2016, now, or 100 years from now, had anything to do with its demise.
It borrowed more money than it could afford to pay back. Therefore the creditors became the owners of the company.
There were numerous news articles going back to 2015 that explained the dire financial condition that Sunedison was in.
How well the solar industry does in the years going forward has absolutely nothing to do with the value of this stock which is absolutely worthless.
BAA is going to be issuing about 800 million new shares.
Whether the new owners are planning on selling sometime soon is more important than the price of goal.
NWBO's latest loan amounted to over 80% interest as I documented in an earlier post. AFAIK that's a huge flashing neon light that the company has no ability to show that it has any value at all.
p.s. I googled: unsecured loans
The first link showed a loan with an interest rate of 14.49%.
As I said before you can interpret the data however you wish, but I think it's pretty clear that for years NWBO hasn't been able to present any reasonable story that would allow it to borrow money on as good a terms as an ordinary deadbeat.
VIX being pre-loaded, up 5% when S&P is even for the day
We seem to have these patterns.
No volatility, futures flat.
No volatility, futures go up a few percent.
No volatility, futures crash.
Actual volatility over the last 10 days is still very low at 8.13.
UVXY needs the VIX to go to 13.65 just to breakeven for the futures being bought now.
http://www.vixcentral.com/
'if this is so good, how come nobody is offering a partnership on decent terms'?
You ask a very good question. More broadly why can't they even get a 20 million dollar one year loan at 20% interest (worse than most people's credit card debt)?
My go-to explanation, regarding horrible looking financing, is that the SEC requires extensive disclosure for companies offering to sell securities and that the information that NWBO (or any company) has to disclose isn't very favorable.
Of course that's just my opinion, but it's usually pretty accurate.
All the discussion these days, about the next big (LOL!) thing, for Mannkind is a pediatric study for Afrezza.
Lots of threads about it, for example:
http://mnkd.proboards.com/thread/7419/pediatric-study
You might be looking for clues about demand. Sanofi started an FDA trial, and left it open for enrollment for months. How many applicants did they get who were willing to get Afrezza for free?
Hundreds!
Thousands!
No, two people signed up.
Afrezza really is the drug you can't give away.
The article is clear. All assets will be divided up among the creditors.
If you buy stock, you're not a creditor.
p.s. I've suggested for months that if anyone wanted to own part of this company they become a creditor by buying bonds.
Is Ihub going to give us freebs more free posts per day now that trump is allowing you, your aunt and everyone else to take and sell any of our personal information to the highest bidder any time anybody wants?
It's always been legal. It was going to become illegal, for a very small group of companies, this fall.
Major broadband providers will have about one year to make the changes required by the new rules; the companies must notify users of their new privacy options in ways like email or dialogue boxes on websites. After the rules are in effect, broadband providers will immediately stop collecting what the F.C.C. deems sensitive data, including Social Security numbers and health data, unless a customer gives permission.
https://www.nytimes.com/2016/10/28/technology/fcc-tightens-privacy-rules-for-broadband-providers.html
There's a bunch of good articles when you google: ethics non-inferiority trials
At the very least it's a great shame when companies mislead investors about the efficacy of a drug that has proven nothing more than "non-inferiority".
There are people at the Proboards site who think Afrezza cures diabetes.
You won't have to worry about SUNEQ trading much longer.
Since it's absolutely worthless, it'll be canceled someday and it'll just stop trading.
Since the company owes a few billion dollars more than it has each share is worth about negative 7 dollars. But the good news is that you can't lose more than put into it (I can't truthfully use the word invest).
In case anyone is interested, you can removed the strange links that look like this shares by adding empty formatting to your keywords.
For example shar[b ][/ b]es without the spaces after the b produces shares
17 dollars would've been almost 7 billion dollars.
Are you claiming that Mannkind sold 65% of the profits for 150 million, and could've sold 100% for 7 billion?
Afrezza shouldn't be on the market. The FDA shouldn't allow non-inferiority trials. For a new drug to be approved it should have to prove that it's better than the alternatives.
You have a drug that's:
1. More expensive than the competition
2. Not better than the competition
3. Only for the handful of people who are afraid of needles.
Optimism over the economy is unwarranted for the most part because the numbers aren't supporting it.
A broad list of economic indicators are at their highest level in over 10 years.
quote: “After six consecutive monthly gains, the U.S. LEI is at its highest level in over a decade.
Which economic numbers are you watching that are indicating a worsening economy?
https://www.conference-board.org/data/bcicountry.cfm?cid=1
Here's the actual historical volatility over the last 10, 20 and 30 days.
10: 8.13
20: 8.21
30: 7.40
The VIX is at 11.42. So option traders are still paying a large (more than 40% (11.42/8.13)) premium over actual volatility.
As I've been saying for months, I don't think buying any of these long volatility products is a good idea until we see actual volatility in the market.
The middle does not have a long tail on its own.
I suspect you're wrong about that, for reasons already stated. But maybe you're right, that it's obvious the drug is effective just from the length of the trial and the company is desperately selling shares at 25 cents because they like to enrich their financiers.
Because there is no market. Nobody is searching for a product like Afrezza.
A huge percentage of the people who try Afrezza drop it. That was even true of the FDA trial; lots of drop-outs.
New Slogan: Try it, you'll hate it.
The Market Does Not Know About Afrezza
If anyone had a need for an inhaled drug that was non-inferior (no better than) the existing treatment they could find out about this turd in a few seconds of googling.
If Linda even suspected that the drug worked the price would be higher.
then that is your choice but then don't complain when others call your hindsight position out on that
What? I've never discussed message board posters. Let's discuss this horrible stock, please!
The most likely reason that people are living longer, in both arms, is that NWBO only accepted people into the trial who didn't progress 2 months after surgery.
Most of them, even those not receiving DC-VAX, didn't suddenly progress the next day.
Shocking news huh?
SORRY. But FEB 1,2017 is perfect time to announce RS
Post a few moments later: From Joeyohso: What moron would hold a conference call to talk about a reverse split? Try again
Mannkind share price down 55% since it's high on Feb 1.
As a pat on the back to this iHub board: No place else has more accurate information.
What's dark about NWBO is that they allowed expectations, and the sharp price, to rise unrealistically.
Rather than selling shares at the top, and raising capital so that they could afford to finish their clinical trial without obscene dilution, they allowed shorts to be the ones supplying stock to an eager public who didn't realize how far off any potential approval might be.
Remember stocks with little cash and high short interest are ones where shorts were selling high to buy low later.
Shorts at sold at 10 bucks a share. NWBO is busy selling shares at 25 cents a share. Shorts made better choices than management did.
Things look bleak. This is the all-time lowest close.
From its price back in 2014.
For example 8/1/2014 Market cap was over 3 billion, but falling rapidly.
https://web-beta.archive.org/web/20140801210211/http://finance.yahoo.com/q/ks?s=MNKD+Key+Statistics
I'd been screaming, from the roof-tops, about this being the most overpriced stock in the world:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103571064
It's what's wrong with 99% of the discussion of efficacy.
The #1 factor determining whether someone has had an event is their age. That's the most obvious thing in the world. Yet I've seen no analysis at all along those lines.
Obviously real investors who have decided not to buy this stock have considered it.
The second important factor that's often overlooked is that the current SOC costs over 20K a month, and how fast is a drug that significantly adds to that cost going to sell?
The reverse split has affected the price paid per share. Our holding have been devalued.
The number of shares you own times the price is EXACTLY THE SAME pre and post split.
Everything I told you was 100% accurate. The real value of TVIX is published constantly when the market is open. It didn't change when the number of shares changed.
I believe it's the median age.
This is the link I use to understand the costs, demographics, survival rates, etc.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070631/
Glioblastoma multiforme is the most common malignant primary brain tumor in adults, with an estimated incidence of 4.43 per 100,000 person-years in the United States and a median age at presentation of 64 years.
TVIX trades according to the value of the assets it holds.
They even have a special ticker that tells you what it's really worth.
Yahoo quotes are hit and miss for accuracy but this link works:
http://finance.yahoo.com/quote/%5Etvix-iv
A reverse split means ABSOLUTELY NOTHING to how it trades.
This was probably the most desperate one-sided loan deal in the history of biotech stock trading.
The deal is so one-sided that they made NWBO include a provision that they could participate in the next NWBO giveaway.
Think about it for a minute. They forced NWBO to include a provision saying: next time you want to shaft your shareholders you're forced to include us. And they put it right in the agreement for everyone to see, they have pride in it.
Importantly it also means that if NWBO attempts to borrow money, they'll know in advance and be able to trade profitably before the news is revealed to ordinary shareholders.
4.12 Participation in Future Financing.
(a) From the date hereof until the date that is the four (4) month anniversary of the Closing Date, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a “Subsequent Financing”), each Purchaser with a Subscription Amount of at least $3,750,000 at Closing (a “Participation Right Purchaser”) shall have the right to participate in up to an amount of the Subsequent Financing equal to 50% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent Financing.
I can't believe all the speculation about a simple patent being granted. Mannkind routinely files new patent applications for technosphere and insulin delivery products.
One of the first Mannkind patent applications was filed in 1997. That means it's expiring this year
Think about that for a minute. 20 years of patent protection for a company that can't produce a marketable product.
Here's an excellent article about what it means when a patent is granted. Importantly, it doesn't mean that everything claimed about the product's benefits are true.
https://www.avvo.com/legal-answers/do-you-have-to-prove-something-works-in-order-to-r-1672237.html
Note: I interpret this as a desperate attempt to ensure that if they ever have anything that people want to buy in numbers that are profitable, it has patent protection.
I wouldn't trust yahoo quotes, or yahoo in general for anything, but the symbol appears like this there:
http://finance.yahoo.com/quote/%5EJNUG-IV
anyone seeing that strange trading on Level 2?? first ask NSDQ selling at 6.58 while price stays at 6.65. is that only me seeing that?
Direxion the manager of JNUG publishes the true value of JNUG during the day under the symbol JNUG.IV. When people pay more than it's worth then professional traders (arbitrageurs) stop in to fix the pricing discrepancy.
http://www.direxioninvestments.com/products/direxion-daily-junior-gold-miners-bull-3x-etf
Compare the two companies.
Mannkind had:
1. an astronomical 3 billion dollar market cap
2. no cash to bring its product to market
3. no niche except people who have a psychological fear of needles
4. a huge short interest
FLXN:
1. sells for 800 million more than its cash level
2. services an unmet need for people who are in for a lifetime of chronic pain
3. a nominal short interest
I was here after the Sanofi deal pointing out that its terms were the most obvious sell signal in the world. Up until the last week before Sanofi dumped Mannkind everyone was saying what a great job Sanofi was doing.
In any case, going forward without Sanofi is going to mean massive dilution. The bad news for Mannkind is right around the corner. It's going to be no more easy days.
I'm unaware of lots of products I have no need for. But if I have a need for something, I tend to search out a product that will help me.
There is no need for Afrezza. It's a solution to a non-existent problem. People aren't needle-phobic in large numbers. Nobody is searching for an insulin that they can inhale as they start eating, because they cough too little now while they eat their appetizer.
I have 3 people I know here in Europe that have Diabetes and not one of them had heard of Afrezza when i mentioned it.
You know why? None of them had a problem with their insulin that they needed to solve. If they did, they could/would have found out about Afrezza very easily.
That's the way people are. If they have a need for something they search out a solution to solve their problem. Remember the FDA trial for Afrezza proved that it was not inferior to the competition. It didn't prove it was better.
Good question.
Northwest took years, and had to go multiple countries, to find two hundred people who wanted to take DCVAX for free. It's certainly possible that there's a few people in the world who believe that it won't be the best-selling drug of all time.
Their market value for their injected insulin products is about $8BN-$10BN annually. Sabotaging the competition for $170M upfront payment was peanuts for them.
The people spreading that story were shorts who wanted to short a bunch of overpriced stock and get rich. They made many 100s of millions of dollars.
Sadly the truth is that Afrezza is a very unpopular product that very few people decide to keep using after they've tried it.